A trial looking at everolimus for kidney cancer that has spread (RAPTOR)
Cancer type:
Status:
Phase:
This trial looked at everolimus for papillary renal cell cancer that had spread to another part of the body. Everolimus is also called RAD001 and Afinitor.
The trial was open for people to join between 2009 and 2011. The team published the results in 2016. There is a link to more information in the ‘Summary of results’ section below.
More about this trial
Renal cell cancer is the most common type of kidney cancer in adults. This trial was for people who had a particular type of renal cell cancer called papillary renal cell cancer. This is less common than some other types.
When this trial was done, doctors often used interferon and interleukin 2 to treat kidney cancer. In this trial they looked at everolimus, a type of targeted treatment.
Everyone in this trial had the same treatment – two everolimus tablets, once a day.
The main aims of this trial were to find out:
- if everolimus is useful for papillary renal cell cancer that has spread
- more about the side effects
Summary of results
We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this trial.
There is more information about the results in the link below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis
B Escudier and others
European Journal of Cancer, 2016. Volume 69, pages 226 to 235.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Paul Nathan
Supported by
Experimental Cancer Medicine Centre (ECMC)
Novartis
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
